Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dantrolene is an HDL-associated paraoxonase-1 activator with immunosuppressive and atheroprotective properties.
Dedemadi AG, Sevdali E, Georgiadou D, Valanti EK, Neofotistou-Themeli E, Chanis T, Goutakoli P, Thymiakou E, Drakos E, Christopoulou G, Bournazos S, Constantoulakis P, Verginis P, Kardassis D, Stratikos E, Sidiropoulos P, Chroni A. Dedemadi AG, et al. Among authors: sidiropoulos p. Biochim Biophys Acta Mol Cell Biol Lipids. 2025 Jan 20:159596. doi: 10.1016/j.bbalip.2025.159596. Online ahead of print. Biochim Biophys Acta Mol Cell Biol Lipids. 2025. PMID: 39842506
Combination of clinical factors predicts successful glucocorticoid withdrawal in systemic lupus erythematosus (SLE): results from a multicentre, retrospective cohort study.
Katechis S, Pitsigavdaki S, Nikoloudaki M, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Govoni M, Sidiropoulos P, Boumpas DT, Fanouriakis A, Bertsias G, Bortoluzzi A. Katechis S, et al. Among authors: sidiropoulos p. RMD Open. 2025 Jan 6;11(1):e005118. doi: 10.1136/rmdopen-2024-005118. RMD Open. 2025. PMID: 39762120 Free PMC article.
Attainment of EULAR/ERA-EDTA targets of therapy with current immunosuppressive regimens and adjustments in treatment: a multicentre, real-life observational study.
Pappa M, Kosmetatou M, Pieta A, Nikoloudaki M, Liapis NM, Tsalapaki C, Chalkia A, Argyriou E, Dimitroulas T, Cheila M, Demirtzoglou G, Papagoras C, Goules A, Katsiari C, Vassilopoulos D, Sidiropoulos P, Boki KA, Sfikakis PP, Liapis G, Gakiopoulou H, Voulgari PV, Boumpas DT, Bertsias G, Tektonidou MG, Fanouriakis A. Pappa M, et al. Among authors: sidiropoulos p. RMD Open. 2024 Sep 18;10(3):e004437. doi: 10.1136/rmdopen-2024-004437. RMD Open. 2024. PMID: 39299738 Free PMC article.
Improvement of high-density lipoprotein atheroprotective properties in patients with systemic lupus erythematosus after belimumab treatment.
Dedemadi AG, Gkolfinopoulou C, Nikoleri D, Nikoloudaki M, Ruhanen H, Holopainen M, Kakela R, Christopoulou G, Bournazos S, Constantoulakis P, Sidiropoulos P, Bertsias G, Chroni A. Dedemadi AG, et al. Among authors: sidiropoulos p. Rheumatology (Oxford). 2024 Mar 21:keae192. doi: 10.1093/rheumatology/keae192. Online ahead of print. Rheumatology (Oxford). 2024. PMID: 38514392
Comorbidities Burden and Implementation of the Treat-to-Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides.
Flouri ID, Repa A, Avgoustidis N, Pitsigavdaki S, Pateromichelaki K, Marolachaki E, Terizaki M, Nikoloudaki M, Eskitzis A, Kalogiannaki E, Bertsias G, Sidiropoulos P. Flouri ID, et al. Among authors: sidiropoulos p. Mediterr J Rheumatol. 2023 Jul 31;34(4):581-587. doi: 10.31138/mjr.310723.cba. eCollection 2023 Dec. Mediterr J Rheumatol. 2023. PMID: 38282943 Free PMC article.
Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression.
Pitsigavdaki S, Nikoloudaki M, Garantziotis P, Silvagni E, Repa A, Marangoni A, Flouri I, Avgoustidis N, Parperis K, Fanouriakis A, Govoni M, Sidiropoulos P, Boumpas DT, Bortoluzzi A, Bertsias G. Pitsigavdaki S, et al. Among authors: sidiropoulos p. Ann Rheum Dis. 2024 Mar 12;83(4):464-474. doi: 10.1136/ard-2023-224919. Ann Rheum Dis. 2024. PMID: 38233103 Free PMC article.
A Peripheral Blood Signature of Increased Th1 and Myeloid Cells Combined with Serum Inflammatory Mediators Is Associated with Response to Abatacept in Rheumatoid Arthritis Patients.
Goutakoli P, Papadaki G, Repa A, Avgoustidis N, Kalogiannaki E, Flouri I, Bertsias A, Zoidakis J, Samiotaki M, Bertsias G, Semitekolou M, Verginis P, Sidiropoulos P. Goutakoli P, et al. Among authors: sidiropoulos p. Cells. 2023 Dec 9;12(24):2808. doi: 10.3390/cells12242808. Cells. 2023. PMID: 38132128 Free PMC article.
The SYSCID map: a graphical and computational resource of molecular mechanisms across rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease.
Acencio ML, Ostaszewski M, Mazein A, Rosenstiel P, Aden K, Mishra N, Andersen V, Sidiropoulos P, Banos A, Filia A, Rahmouni S, Finckh A, Gu W, Schneider R, Satagopam V. Acencio ML, et al. Among authors: sidiropoulos p. Front Immunol. 2023 Nov 1;14:1257321. doi: 10.3389/fimmu.2023.1257321. eCollection 2023. Front Immunol. 2023. PMID: 38022524 Free PMC article.
178 results